Search research articles
Contact Us
Filters
Showing results (371-380 of 395) with videos related to
Page
of 40
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 26, 2018
Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies
Justin I Odegaard, John J Vincent, Stefanie Mortimer, et al.
Breast Cancer Research : BCR
|
May 24, 2024
Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer
Samuel A Jacobs, Ying Wang, Jame Abraham, et al.
Breast Cancer Research : BCR
|
April 22, 2024
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer
Samuel A Jacobs, Ying Wang, Jame Abraham, et al.
JCO Precision Oncology
|
June 7, 2021
Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy
Jeffrey C Thompson, Erica L Carpenter, Benjamin A Silva, et al.
JCO Precision Oncology
|
August 21, 2018
Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer
Zofia Piotrowska, Mehlika Hazar-Rethinam, Coleen Rizzo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 20, 2018
Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing
Thomas P Slavin, Kimberly C Banks, Darya Chudova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 23, 2020
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer
Ibiayi Dagogo-Jack, Satoshi Yoda, Jochen K Lennerz, et al.
Cancer
|
March 9, 2018
Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA
Neeraj Agarwal, Sumanta K Pal, Andrew W Hahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 28, 2020
Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer
Charu Aggarwal, Jeffrey C Thompson, Austin L Chien, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 4, 2018
Amplification of Wild-type <i>KRAS</i> Imparts Resistance to Crizotinib in <i>MET</i> Exon 14 Mutant Non-Small Cell Lung Cancer
Magda Bahcall, Mark M Awad, Lynette M Sholl, et al.
Page
of 40
Search research articles
Search
Showing results (371-380 of 395) with videos related to
Sort By:
Page
of 40
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 26, 2018
Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies
Justin I Odegaard, John J Vincent, Stefanie Mortimer, et al.
Breast Cancer Research : BCR
|
May 24, 2024
Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer
Samuel A Jacobs, Ying Wang, Jame Abraham, et al.
Breast Cancer Research : BCR
|
April 22, 2024
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer
Samuel A Jacobs, Ying Wang, Jame Abraham, et al.
JCO Precision Oncology
|
June 7, 2021
Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy
Jeffrey C Thompson, Erica L Carpenter, Benjamin A Silva, et al.
JCO Precision Oncology
|
August 21, 2018
Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer
Zofia Piotrowska, Mehlika Hazar-Rethinam, Coleen Rizzo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 20, 2018
Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing
Thomas P Slavin, Kimberly C Banks, Darya Chudova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 23, 2020
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer
Ibiayi Dagogo-Jack, Satoshi Yoda, Jochen K Lennerz, et al.
Cancer
|
March 9, 2018
Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA
Neeraj Agarwal, Sumanta K Pal, Andrew W Hahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 28, 2020
Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer
Charu Aggarwal, Jeffrey C Thompson, Austin L Chien, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 4, 2018
Amplification of Wild-type <i>KRAS</i> Imparts Resistance to Crizotinib in <i>MET</i> Exon 14 Mutant Non-Small Cell Lung Cancer
Magda Bahcall, Mark M Awad, Lynette M Sholl, et al.
Page
of 40